EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSJJAG00000018427
Gene Symbol: GRIK1
3 Cross references
302 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSJJAG00000019973
Gene Symbol: GRIK2
3 Cross references
331 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSJJAG00000017762
Gene Symbol: GRIK3
3 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSJJAG00000022344
Gene Symbol: GRIK4
3 Cross references
261 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSJJAG00000015626
Gene Symbol: GRIK5
3 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSJJAG00000019080
Gene Symbol: GRM2
3 Cross references
276 Possible Orthologues:

Glutamate Metabotropic Receptor 3

Ensembl ID : ENSJJAG00000019396
Gene Symbol: GRM3
3 Cross references
215 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSJJAG00000022598
Gene Symbol: GRM4
3 Cross references
273 Possible Orthologues:

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSJJAG00000024148
Gene Symbol: GRM5
3 Cross references
271 Possible Orthologues:

Glutamate Receptor, Ionotropic, Nmda2d (Epsilon 4)

Ensembl ID : ENSJJAG00000003385
Gene Symbol: GRIN2D
1 Cross references
278 Possible Orthologues:

Glutaminase

Ensembl ID : ENSJJAG00000019300
Gene Symbol: GLS
3 Cross references
305 Possible Orthologues:

Glutathione S-Transferase P

Ensembl ID : ENSJJAG00000023512
Gene Symbol: LOC101605408
2 Cross references
172 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).